coplug
    Back to PCN explorer
    PCN reports · Core20PLUS5

    Ardwick And Longsight PCN, Manchester (LAD) · Health Inequalities Profile

    PCN U07506 · NHS Greater Manchester Integrated Care Board · 10 GP practices

    Read the report

    This report is generated by Coplug's Healthcare Agent. Log in to ask further questions of it, add the spatial context, or create new enquiries to better understand and improve your Neighbourhood's Health

    01 / 15

    Board summary

    Key figures

    88,617

    Registered population

    75.5% aged 18–64

    6.4%

    Aged 65+

    ICB 14.9% · England 17.9%

    56.7%

    Ethnic minority (non-White)

    35.2% Asian · England 9.6%

    72.8%

    In IMD quintile 1

    ICB 40.7% · England 21.0%

    ~32,691

    Core20 residents (est.)

    Resident basis; registered basis ~60,282 · see page 3

    7,749

    Hypertension register

    +5.84% in 3 yrs · England +5.60%

    976

    SMI register

    10.3% of Manchester (LAD)'s

    1,039

    COPD register

    Reviews -18.66% in 3 yrs

    Forecast to 2030

    8,720

    Hypertension patients, 2030

    +971 on today

    82.9%

    QRISK ≥20% on statins, 2030

    +3.12pp over 3 yrs

    1.6%

    Cancer prevalence, 2030

    England 4.5%

    Three things the board should see

    -18.7%
    Respiratory reviews fall as COPD register grows.

    Annual COPD reviews changed -18.7% to 66.0% (England 76.4%) despite +8.5% register growth, while 1,579 asthma patients lack a recorded review.

    43.7%
    Cervical screening and age-five boosters lag.

    Cervical screening in ages 25-49 is 43.7% (England 66.8%, 3-year change -5.8%), and age-5 MMR2 is 67.0% versus 89.2% for MMR1 (22.2 pp difference).

    76.3%
    Statin prescribing and SMI checks beat comparators.

    Lipid-lowering therapy for QRISK ≥ 20% reaches 76.3% (England 63.6%, Manchester 70.5%, ICB 67.0%), while SMI BP and BMI checks both reach 83.8%.

    Sources & context

    PCN and practice-level primary care data; ICB and provider context on page 8

    Powered by Coplug · Page 1 of 15
    02 / 15

    Population, age and ethnicity

    A registered list of 88,617 has 75.5% aged 18-64 and 6.4% aged 65+

    Across member practices, the PCN has 88,617 registered patients. The population is working-age: 75.5% (66,887 patients) are aged 18-64, exceeding Manchester (LAD) at 68.9%, NHS Greater Manchester Integrated Care Board at 63.3% and England at 62.7%. Only 6.4% (5,676 patients) are aged 65+, below Manchester (9.6%), the ICB (14.9%) and England (17.9%). By Census usual-resident estimates, not registered patients, 56.7% are from ethnic minority groups, led by Asian or Asian British residents at 35.2% (Manchester 20.9%, England 9.6%), reaching 62.8% at Parkside Surgery and 51.3% at Dickenson Road Medical Centre.

    Age profile

    0–1718.1%
    18–6475.5%
    65+6.4%

    65+: ICB 14.9%, England 17.9%

    Ethnicity

    White43.3%
    Asian35.2%
    Black11.8%
    Other5.9%
    Mixed3.8%

    Older people · falls rows are Manchester (LAD) local-authority (LA) data, not PCN

    MeasureLocalNorth WestEnglandPeriod
    Falls admissions, 65+, per 100,000 (Manchester LA)2,3572,0711,9582024/25
    Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN)80.3%82.9%81.9%2024/25
    Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN)55.8%56.6%57.4%2024/25
    Falls admissions, 65 to 79, per 100,000 (Manchester LA)1,2811,0219552024/25
    Falls deaths, all ages, per 100,000 (Manchester LA)26.818.214.82022‑24
    Sources & context

    Census 2021; Fingertips falls and diabetes. Falls are local-authority data. Ethnic minority = 100% minus White

    Powered by Coplug · Page 2 of 15
    03 / 15

    Deprivation and Core20

    Core20 patients comprise 72.8% of the PCN, with practice shares spanning 76.5 pp

    Core20 patients make up 72.8% of the PCN, above Manchester (59.8%), the ICB (40.7%) and England (21.0%), with an average IMD decile of 2.4 (England 5.5). Practice Core20 shares span 76.5 pp, from 23.5% at Vallance Medical to 100.0% at Parkside Surgery. Denominators diverge: the resident Core20 estimate is 32,691 while practice-summed registered estimates reach 60,282 (weighted practice share 68.0%). Targeting by Core20 concentration highlights Parkside Surgery (100.0%), whereas volume targeting points to Manchester Integrative Medical Practice (10,828 patients).

    % of patients in IMD quintile 1, by practice

    Dashed line: England 21.0% · right column: Core20 patients, registered basis

    Parkside100.0% · 7,001 patients
    Dickenson Road97.9% · 8,877 patients
    New Bank Health97.1% · 5,792 patients
    Ailsa Craig86.4% · 8,973 patients
    Ardwick Medical79.1% · 4,194 patients
    Manchester77.0% · 10,828 patients
    Brunswick Medical57.9% · 4,364 patients
    Surrey Lodge48.4% · 4,307 patients
    Wilmslow Road46.9% · 2,333 patients
    Vallance Medical23.5% · 3,613 patients
    Sources & context

    Deprivation: Index of Multiple Deprivation, applied to registered patients

    Powered by Coplug · Page 3 of 15
    04 / 15

    PLUS groups and inclusion health

    PLUS groups and inclusion health

    976

    SMI register

    1.05% recorded prevalence

    566

    Learning disability register

    0.61% recorded prevalence

    13

    Care homes, 243 beds

    In the PCN catchment

    8.7%

    Provide unpaid care

    Manchester (LAD), Census 2021

    The PCN records 976 patients on the severe mental illness register (1.1%) and 566 on the learning disability register (0.6%), alongside 13 catchment care homes (243 beds). At local authority level, Manchester recorded 55 rough sleepers in the autumn 2025 snapshot, whereas PCN-level homelessness counts were not captured.

    Severe mental illness: physical health checks

    Recorded SMI blood pressure checks reached 83.8% (England 83.4%) and BMI recording reached 83.8% (England 82.1%), while alcohol recording reached 84.9% (England 81.8%). Other check elements were not captured; published rates cannot establish full check completion.

    Sources & context

    QOF registers; Census 2021 carers; care homes and homelessness as supplied. Carers and homelessness are local-authority data

    Powered by Coplug · Page 4 of 15
    05 / 15

    Clinical focus: hypertension and lipids

    Clinical focus: hypertension and lipids

    7,749

    Hypertension register

    +5.84%

    Register growth, 3 yrs

    Manchester (LAD) +4.49% · England +5.60%

    +0.75pp

    BP control, under 80

    ≤140/90 · +1.22pp aged 80+

    +971

    More patients by 2030

    Forecast 8,720 (9.31%)

    Hypertension case-finding and control

    Ardwick and Longsight PCN records a hypertension prevalence of 8.3% (7,749 patients), below Manchester (10.5%), the ICB (14.4%) and England (15.2%), though crude recorded prevalence does not establish under-detection in a population where 75.5% are aged 18-64. Recent blood pressure checks reach 90.2% (England 90.0%). Blood pressure control to <= 140/90 mmHg in patients aged under 80 reaches 66.2%, trailing the ICB (68.6%) and England (67.8%), with three-year growth of +1.1% lagging England (+3.2%). Blood pressure treated to target sits at 68.4% (England 70.3%, ICB 71.4%). Blood pressure control among patients under 80 lags regional and national benchmarks.

    Lipids and statins

    Patients with QRISK ≥ 20% treated with lipid lowering therapy reach 76.3% (England 63.6%, Manchester 70.5%, ICB 67.0%). Among patients with diabetes aged 40 and over without cardiovascular disease, statin treatment is 84.6% (England 73.2%, Manchester 79.8%, ICB 75.7%).

    MeasureItemsCost / itemICBEnglandAnnual spend
    Lipid-modifying, 2026125,825£3.40£1.94£1.86£427,805
    Cardiovascular (all), 2025138,415£2.32£3.15£3.33£321,123

    Lipid-regulating drugs cost £3.40 per item in 2026 across 125,825 items (£427,805 spend), compared to £1.86 for England and £1.94 for NHS Greater Manchester Integrated Care Board. Across 125,825 items, this represents £193,770 more than at England's unit cost.

    Sources & context

    QOF hypertension register and BP control indicators; prescribing items and cost as supplied

    Powered by Coplug · Page 5 of 15
    06 / 15

    Clinical focus: respiratory, cancer register and children

    Clinical focus: respiratory, cancer register and children

    Respiratory

    −3.20%

    Asthma reviews, PCN 3-yr % change

    +4.44%

    Asthma reviews, England 3-yr % change

    −3.23%

    Asthma prevalence, PCN 3-yr % change

    The COPD register grew +8.5% over 2023 to 2025 (England +2.6%) to 1,039 patients, while annual COPD reviews fell 18.7% (England +2.8%) to 66.0% (England 76.4%, Manchester 74.5%, ICB 76.4%). Asthma reviews fell 3.2% over 2023 to 2025 (England +4.4%) to 61.8% (England 65.7%), leaving about 1,600 patients unreviewed across 4,135 on the register. Second-hand smoking recording for asthma patients aged 6-19 is 66.2% (England 78.8%).

    Cancer register and children's immunisation

    Recorded cancer prevalence is 1.3% (England 3.8%). In Q1 2025/26, age-5 MMR coverage was 89.2% for dose 1 but 67.0% for dose 2 (England 82.8%), a 22.2 pp difference. The 4-in-1 booster coverage at age 5 reached 63.1% (England 80.9%, ICB 80.5%). At 12 months, 6-in-1 coverage reached 81.4% (England 91.0%, ICB 88.7%).

    Dashed line: 95% national coverage target · solid tick: England

    6-in-1 at 12 months81.4%

    England 91.0%

    6-in-1 complete primary course at 24 months90.1%

    England 92.2%

    MMR dose 1 at 24 months84.5%

    England 88.3%

    MMR dose 2 at age 567.0%

    England 82.8%

    4-in-1 pre-school booster at age 563.1%

    England 80.9%

    Sources & context

    QOF registers and review indicators; childhood immunisation coverage as supplied

    Powered by Coplug · Page 6 of 15
    07 / 15

    Early cancer diagnosis

    Early cancer diagnosis

    55.6%

    Greater Manchester ICB, stage 1–2

    55.3%

    England, 2022

    75%

    National ambition by 2028

    ~2,270

    Extra early-stage cases a year to reach the ambition

    Stage 1–2 share by cancer type, 2022Greater Manchester ICBEnglandNo usable stageStaged cancers
    Lung40.4%33.8%15%2,193
    Prostate61.7%53.2%14%1,788
    Breast82.5%85.4%19%1,758
    Bowel46.3%47.0%19%1,427
    Skin cancer84.5%87.8%27%580

    In 2022, 55.6% of staged cancers across NHS Greater Manchester ICB were diagnosed at stage 1 or 2 (6,491 of 11,679 staged cases), in line with England (55.3%) but below the 75.0% national ambition by 19.4 pp. Reaching that ambition would require about 2,270 additional early-stage diagnoses annually across the ICB, where known-stage coverage was 70.8% (11,679 of 16,492 registered cancers). These system-level figures do not represent PCN performance. However, PCN cervical screening coverage in women aged 25-49 is 43.7% (England 66.8%, Manchester 57.2%, ICB 65.9%), having fallen -5.8% over three years. Persistent screening shortfalls may delay early detection and leave symptom presentation to later stages.

    Sources & context

    Stage at diagnosis: National Disease Registration Service

    Powered by Coplug · Page 7 of 15
    08 / 15

    Cancer waits, diagnostics and community services

    Cancer waits, diagnostics and community services

    Cancer waits and diagnostics, Jul 2026 (provisional)

    At Manchester University NHS Foundation Trust, the 62-day referral to treatment performance was 72.8%, falling below the 85.0% standard by 12.2 pp, compared to 75.7% across NHS Greater Manchester Integrated Care Board (9.3 pp below standard). The trust met the 28-day faster diagnosis standard at 80.1% (5.1 pp above the 75.0% standard; ICB 79.5%), but trailed the 31-day combined treatment standard at 92.5% (below the 96.0% standard by 3.5 pp). These acute operational pressures indicate that while initial diagnosis is prompt, treatment commencement faces secondary-care pathway delays. Secondary-care treatment backlogs mean practice teams must actively monitor referred patients awaiting definitive.

    Pathways within standard (%)ManchesterNorthern Care AllianceStockportGreater Manchester ICBEngland
    28-day faster diagnosis (75%)80.0675.2083.2179.5379.32
    31-day treatment (96%)92.5494.5497.3996.4992.50
    62-day referral to treatment (85%)72.8578.6574.6775.7371.16
    Diagnostic waits over 6 weeks (%)ManchesterNorthern Care AllianceStockportEngland
    MRI11.685.091.4121.40
    CT14.664.102.939.92
    Echocardiography4.9131.4817.4628.48
    Colonoscopy4.5140.045.5330.83
    Gastroscopy29.3536.485.3129.02
    All 15 DM01 tests8.9815.7114.0823.14
    Community services activityManchester residentsGreater Manchester ICB
    Care contacts96,995573,310
    Referrals20,27094,470
    Patients with a contact31,040183,535

    Community services (residents of Manchester), Jun 2026 (provisional). In provisional Community Services Dataset reporting for June 2026, adults aged 65 and over accounted for 43.3% of community contacts among Manchester borough residents (42,015 of 96,995 contacts). These activity data reflect borough-level community service delivery rather than PCN-specific utilization, underscoring substantial older-adult community resource use across the wider municipal area. Older-adult community contact volume suggests community nurse liaison is vital when supporting frail patients undergoing cancer investigations.

    Sources & context

    Waits and diagnostics: NHS England monthly statistics · ICB and provider data, not PCN

    Powered by Coplug · Page 8 of 15
    09 / 15

    Practice variation and patient experience

    Practice patient satisfaction ranges from 67.3% to 93.3%, alongside variable QOF adjustment rates

    GP Patient Survey by practice

    PracticeResponses% in IMD Q1Phone easyRequest led to apptOverall good
    Brunswick Medical11557.980.9%74.4%93.3%
    Ardwick Medical10779.159.6%90.0%81.5%
    Vallance Medical6023.585.0%70.9%81.3%
    Surrey Lodge11048.463.8%67.4%81.0%
    Wilmslow Road8746.962.5%71.5%80.8%
    Manchester10177.055.4%73.4%78.2%
    Ailsa Craig7986.431.1%72.3%74.0%
    New Bank Health7097.156.5%70.8%72.1%
    Dickenson Road10497.943.5%74.4%68.7%
    Parkside Surgery64100.048.0%83.5%67.3%
    England—~2156.9%71.6%76.7%
    Sources & context

    QOF achievement; GP Patient Survey, practice-level results

    Powered by Coplug · Page 9 of 15
    11 / 15

    What the data can't tell us: gaps and local assets

    What the data can't tell us: gaps and local assets

    Local assets and voluntary sectorPCNManchester (LAD)AssetPCNManchester (LAD)
    Care homes (catchment)13 (243 beds)n/aSchools (catchment)90n/a
    Children's centres834Places of worship75289
    Libraries416Homelessness support (VCS)n/a1
    Primary schools (LA maintained)1868Primary academies450
    Special schools13

    0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.

    Sources & context

    Gaps are modelled estimates against benchmark rates; local assets as supplied

    Powered by Coplug · Page 11 of 15
    12 / 15

    Options for the PCN

    Options for the PCN

    Each option in full

    Option 1

    Structured asthma and COPD review recall

    Asthma reviews are 61.8% (England 65.7%; 3-year change -3.2% vs +4.4%), leaving 1,579 of 4,135 patients unreviewed; COPD reviews fell 18.7% to 66.0% (England 76.4%) across 1,039 patients. For discussion: run single-template recall and after-school asthma review slots alongside second-hand smoke recording (66.2% vs England 78.8%). Moderate effort to run.

    Evidence base: the annual asthma review is the process gap between the register and outcomes.

    Policy anchor: Core20PLUS5 chronic respiratory disease priority.

    Option 2

    Hypertension titration and lipid prescribing review

    Under-80s BP control is 66.2% (England 67.8%, ICB 68.6%; 3-year change +1.1% vs England +3.2%); lipid-modifying prescribing costs £3.40 per item, or £193,770 more than at England's £1.86 unit cost across 125,825 items. Moderate effort to run.

    Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.

    Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).

    Option 3

    Culturally adapted screening and booster recall

    Cervical screening (ages 25-49) is 43.7% (England 66.8%; 3-year change -5.8%); age-5 MMR2 is 67.0% versus 89.2% for MMR1 (22.2 pp difference, England 82.8%), and 4-in-1 booster coverage is 63.1% (England 80.9%). Moderate effort to run.

    Evidence base: uptake is the delivery measure of the national cancer screening programme; distance to the acceptable and achievable standards is the outreach target.

    Policy anchor: Shift 3: sickness to prevention; Eliminate cervical cancer by 2040.

    Sources & context

    Options are the profile's; evidence base from Coplug's indicator catalogue

    Powered by Coplug · Page 12 of 15
    13 / 15

    Provenance and audit trail

    Provenance and audit trail

    Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

    RecommendationIndicator(s)Policy anchorData level
    Culturally tailored access review (p2)Asian / Asian BritishNeighbourhood health framework · Core20PLUS5 approachPCN
    Dual track Core20 outreach (p3)Core20 cohort (IMD quintile 1)Core20PLUS5 · 10YHP equity testPCN
    Sustain physical health monitoring (p4)SMI register with a BP check in the last 12 monthsMHIS · From Harm to HopePCN
    Hypertension control recall audit (p5)Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs)Core20PLUS5 CVD · CVDPREVENT 2029PCN
    Pre-school booster recall audit (p6)MMR dose 2 coverage at age 510YHP sickness to prevention · 95% targetPCN
    Cervical screening uptake recovery (p7)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Targeted patient access review (p9)GPPS good overall experience of the practice10YHP, hospital to communityPractice
    Option 1 · Structured asthma and COPD review recall (p12)Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD registerCore20PLUS5 respiratoryPCN
    Option 2 · Hypertension titration and lipid prescribing review (p12)Hypertension register · Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) · Hypertension patients treated to targetCore20PLUS5 CVD · CVDPREVENT 2029PCN
    Option 3 · Culturally adapted screening and booster recall (p12)Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) · Breast screening coverage: aged 53 to 70 years old · Asian / Asian BritishFit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026PCN
    Sources & context

    Re-run this profile in 12 months to see whether the gaps have narrowed

    Powered by Coplug · Page 13 of 15
    14 / 15

    Data sources

    Data sources

    Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

    DatasetLevelPeriodUsed for
    Coplug indicator tables: census, deprivation and QOF measuresPCN & Practice2023 to 2025, projected to 2030; 2023 to 2024Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12
    MHCLG, Rough sleeping snapshot in England: autumn 2025Local authorityAutumn 2025Pages 2, 4
    OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713)PCN2024/25Pages 2, 4
    OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002)Local authority2024/25; 2022-24Pages 2, 4
    ONS, Census 2021 TS039: provision of unpaid care (age-standardised)Local authorityCensus 2021Pages 2, 4
    QOF registers, prevalence and care processes (Coplug indicator tables)Practice2023 to 2025, projected to 2030Pages 4, 5, 6, 7, 8, 10
    UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26PCN & PracticeQ1 2025/26Pages 4, 6
    UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026Local authority2025/26 season to 28 Feb 2026Pages 4, 6
    NHS England, Cancer Waiting Times: July 2026 monthly time series with revisionsICB & ProviderJul 2026 (provisional)Pages 7, 8
    NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental dataICB & Local authorityJun 2026 (provisional)Pages 7, 8
    NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026ProviderJul 2026Pages 7, 8
    National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022ICB2022Pages 7, 8
    NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted)PracticeSurvey Jan-Apr 2026Page 9
    NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domainPractice2025/26Page 9
    NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domainPractice2025/26Page 9
    Coplug indicator catalogue — definitions, cohorts, policy anchorsReferenceCurrentEvidence-base lines, page 13
    Sources & context

    Where a period is given as "as supplied", the source file did not state a vintage

    Powered by Coplug · Page 14 of 15
    15 / 15

    Methods, data-quality notes and limitations

    Methods, data-quality notes and limitations

    Methods

    Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.

    Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.

    Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.

    Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.

    Sources & context

    Estimates size the task; they are not confirmed missed patients

    Powered by Coplug · Page 15 of 15